2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibition in Cancer and Virology

Executive Summary: 2-Deoxy-D-glucose (2-DG) is a glucose analog that competitively inhibits glycolysis, suppressing ATP synthesis and inducing metabolic oxidative stress in various cell types (Li et al., 2024). In KIT-positive gastrointestinal stromal tumor (GIST) models, 2-DG demonstrates cytotoxicity with IC50 values of 0.5 μM (GIST882) and 2.5 μM (GIST430) (APExBIO product page). 2-DG impairs early-stage viral protein translation, inhibiting porcine epidemic diarrhea virus (PEDV) replication in Vero cells. In animal models, combination of 2-DG with Adriamycin or Paclitaxel leads to slower tumor growth in osteosarcoma and non-small cell lung cancer xenografts. The compound is water-soluble at ≥105 mg/mL and is widely used in metabolic pathway and signaling research (GTP Solution, 2023).

Biological Rationale

2-Deoxy-D-glucose (2-DG) is a synthetic glucose analog that enters cells via glucose transporters (GLUTs). Upon phosphorylation by hexokinase, 2-DG-6-phosphate accumulates due to its resistance to further metabolism by phosphohexose isomerase (Li et al., 2024). The resulting inhibition of glycolytic flux causes a drop in cellular ATP levels and increases metabolic oxidative stress. Tumor cells, especially those reliant on aerobic glycolysis (the Warburg effect), are particularly sensitive to glycolytic inhibition. In virology, several viruses require host glycolytic machinery during replication, making 2-DG a relevant tool for studying viral-host metabolic interplay (GTP Solution, 2023). Recent work also links glycolytic perturbation to cytoskeletal regulation via post-translational modifications such as α-tubulin lactylation, establishing a metabolic-cytoskeletal interface (Li et al., 2024).

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

2-DG acts as a competitive glycolysis inhibitor. It is structurally similar to glucose but lacks the 2-hydroxyl group, preventing completion of glycolysis after phosphorylation. Accumulation of 2-DG-6-phosphate inhibits phosphohexose isomerase, blocking the conversion of glucose-6-phosphate to fructose-6-phosphate. This results in:

• Disruption of ATP synthesis: Reduced glycolytic ATP production leads to cellular energy crisis.
• Induction of metabolic oxidative stress: Glycolytic inhibition raises reactive oxygen species (ROS) via altered redox states (Li et al., 2024).
• Suppression of biosynthetic pathways: Decreased glycolytic intermediates reduce nucleotide and lipid synthesis, impairing cell proliferation.
• Inhibition of viral replication: 2-DG impedes early viral protein translation and replication by depriving viruses of host ATP and biosynthetic precursors (APExBIO).
• Impact on cytoskeleton: Metabolic stress influences microtubule dynamics via α-tubulin posttranslational modifications, such as lactylation and acetylation, which are sensitive to glycolytic flux (Li et al., 2024).

Evidence & Benchmarks

• 2-DG exhibits cytotoxicity in KIT-positive GIST cell lines, with IC50 values of 0.5 μM (GIST882) and 2.5 μM (GIST430) (APExBIO, product page).
• In Vero cells, 2-DG impairs PEDV replication by inhibiting viral protein translation during early infection stages (Li et al., 2024).
• Animal models show that 2-DG enhances the efficacy of Adriamycin and Paclitaxel in suppressing tumor growth in human osteosarcoma and non-small cell lung cancer xenografts (APExBIO).
• 2-DG treatment induces metabolic oxidative stress, evidenced by increased ROS and altered redox balance in cancer cells (Li et al., 2024).
• Solubility parameters: ≥105 mg/mL in water, ≥2.37 mg/mL in ethanol (with warming/ultrasonic treatment), ≥8.2 mg/mL in DMSO. Store at -20°C; avoid long-term solution storage (APExBIO, product page).
• Typical in vitro conditions: 5–10 mM, 24-hour exposure for metabolic inhibition (APExBIO).
• 2-DG’s glycolysis inhibition modulates PI3K/Akt/mTOR signaling, impacting cell survival and proliferation (GTP Solution, 2023).

Applications, Limits & Misconceptions

2-DG has broad utility in basic and translational research. In cancer biology, it serves as a tool to dissect glycolytic dependence and redox stress responses. In virology, 2-DG is used to interrogate host-virus metabolic dynamics. It is also pivotal in studying metabolic regulation of cytoskeleton functions, including α-tubulin lactylation and acetylation. The product is suitable for metabolic pathway mapping and screening synergy with chemotherapeutics.

This article builds upon prior mechanistic reviews (see 2-Deoxy-D-glucose (2-DG): Mechanistic Insights in Glycoly...) by integrating recent evidence of cytoskeletal modulation and metabolic-cytoskeletal crosstalk. Unlike scenario-driven guides (Reliable Glycolysis Inhibition ...), this dossier emphasizes atomic, in vitro and in vivo benchmarks, clarifying boundaries for use in immunometabolic and virology pipelines.

Common Pitfalls or Misconceptions

• 2-DG is not a pan-cytotoxic agent: Selectivity depends on glycolytic reliance; non-transformed cells with robust oxidative phosphorylation are less susceptible (Li et al., 2024).
• Not suitable for long-term solution storage: Degradation and loss of activity occur; always prepare fresh solutions for each experiment (APExBIO).
• Variable efficacy in vivo: Systemic metabolism (e.g., hepatic clearance) and off-target effects can limit tumor exposure and therapeutic window.
• Not a direct PI3K/Akt/mTOR inhibitor: 2-DG’s pathway modulation is indirect, via metabolic stress, not by receptor or kinase inhibition.
• Does not replace standard chemotherapeutics: 2-DG is best used in combination regimens or as a research tool, not as monotherapy.

Workflow Integration & Parameters

APExBIO’s 2-Deoxy-D-glucose (2-DG, B1027 kit) provides consistent, high-purity reagent for metabolic research. For in vitro studies, typical concentrations range from 5–10 mM, applied for 24 hours in standard culture media. For virology, dosing at 2.5–10 mM effectively impairs viral replication in Vero and other susceptible lines. Dissolution is optimal at ≥105 mg/mL in water; for DMSO, use ≥8.2 mg/mL. Ethanol requires warming and ultrasonic treatment for ≥2.37 mg/mL solubility. Store lyophilized powder at -20°C and avoid repeated freeze-thaw cycles. For animal studies, dosing regimens must account for systemic clearance and metabolic adaptation. Workflow integration is supported by robust product documentation and batch-level QC (APExBIO scenario guide).

Conclusion & Outlook

2-Deoxy-D-glucose (2-DG) remains a cornerstone for dissecting glycolysis-dependent processes in cancer and viral replication. Its robust, atomic action profile—validated in multiple cell types and xenograft models—enables precise perturbation of metabolic pathways. Recent discoveries, such as the role of metabolism in cytoskeletal modifications, further expand 2-DG’s relevance to cell biology. APExBIO’s B1027 offering ensures reproducibility and reliability for advanced metabolic research. Ongoing work should clarify optimal dosing, resistance mechanisms, and expand its application to new disease models and metabolic-cytoskeletal interfaces (Li et al., 2024).